We are live on ! Find out more
BNTX icon

BioNTech

80.96 USD
-0.42
0.52%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
81.00
+0.04
0.05%
1 day
-0.52%
5 days
-5.43%
1 month
-11.2%
3 months
-26.99%
6 months
-10.4%
Year to date
-16.27%
1 year
-16.51%
5 years
-74.83%
10 years
468.54%
 

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Employees: 7,807

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 39.7%
Neutral 32.8%
Negative 27.6%
Positive
The Motley Fool
1 day ago
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
Both companies are working to move beyond their coronavirus vaccine windfalls. These biotech players aim to make strides in cancer treatment.
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
Positive
Barrons
9 days ago
BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
Positive
The Motley Fool
10 days ago
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Positive
The Motley Fool
12 days ago
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed improving financial performance, alongside promising Phase 3 data for its personalized cancer vaccine.
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
Neutral
24/7 Wall Street
15 days ago
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
Neutral
The Motley Fool
16 days ago
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
Negative
Seeking Alpha
17 days ago
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
Neutral
Seeking Alpha
18 days ago
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Cory Kasimov - Evercore Inc. Terence Flynn - Morgan Stanley, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Welcome to BioNTech's Third Quarter 2026 Earnings Call. I will now hand the call over to Doug Maffei, Vice President of Investor Relations.
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
18 days ago
BioNTech Q3 Earnings Call Highlights
BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.
BioNTech Q3 Earnings Call Highlights
Neutral
GlobeNewsWire
18 days ago
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide Third quarter 2026 revenues of €1,289.2 million1 , adjusted2 R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A3 expenses of €178.5 million Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion4 Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m.
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Price charts implemented using Lightweight Charts™